Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The 5th International Conference on Clinical Trials for Alzheimer's Disease (CTAD) will examine the phase 3 treatment trials of Alzheimer's Disease (AD) and also analyze the results to develop current and new drugs to tackle AD.
Subscribe to our email newsletter
The conference will also discuss the global AD research, which includes improving early detection, proper diagnosis methods, harmonization of imaging techniques across patient populations, identifying factors that affect AD progression and to progress AD biomarkers.
Founded in 2008 and based in France, CTAD is a professional forum for the researchers to share ideas and develop international collaboration to fight Alzheimer’s.
CTAD co-organizer and spokesman Michael Weiner said the research presented at CTAD is important to provide path for global research in Alzheimer’s disease.
"No one country is going to be able to solve Alzheimer’s alone, and we are bringing together the best in the field to spur better discoveries faster, " Weiner added.
The conference will present results from the solanezumab phase 3 studies and imaging and clinical data from the MAPT trial conducted by the researchers from the University of Montpellier and University of Toulouse.